News
CDXS
2.505
-2.91%
-0.075
Codexis spotlights siRNA stereochemistry control at TIDES USA 2026
PUBT · 1d ago
Weekly Report: what happened at CDXS last week (0511-0515)?
Weekly Report · 3d ago
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results
Simply Wall St · 05/11 11:54
Weekly Report: what happened at CDXS last week (0504-0508)?
Weekly Report · 05/11 10:35
Codexis Earnings Call Balances Breakthroughs and Risks
TipRanks · 05/09 00:32
Codexis (CDXS) Q1 2026 Earnings Transcript
The Motley Fool · 05/08 19:32
Codexis reiterates $72M-$76M 2026 revenue outlook while targeting 0.5 kilogram ECO Synthesis scale by year-end
Seeking Alpha · 05/08 18:42
Analysts Offer Insights on Healthcare Companies: Codexis (CDXS), Irhythm Technologies (IRTC) and BridgeBio Pharma (BBIO)
TipRanks · 05/08 14:03
Codexis (CDXS) Gets a Buy from Piper Sandler
TipRanks · 05/08 13:01
Codexis: Neutral Stance Maintained as Execution Risks Offset Solid Q1; $2 Price Target Reaffirmed
TipRanks · 05/08 00:55
Codexis reports Q1 EPS (10c), consensus (10c)
TipRanks · 05/07 22:52
Codexis Q1 revenue more than doubles on Merck agreement
Reuters · 05/07 20:55
Codexis Q1 net loss narrows to $8.7 million; revenue more than doubles to $15.2 million
PUBT · 05/07 20:35
Weekly Report: what happened at CDXS last week (0427-0501)?
Weekly Report · 05/04 10:32
Codexis To Present New Data And Provide Regulatory Update On ECO Synthesis Manufacturing Platform At TIDES USA May 11-14
Benzinga · 04/29 13:03
Codexis to present RNA manufacturing advances at TIDES USA conference
PUBT · 04/29 13:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Codexis (CDXS)
TipRanks · 04/27 14:30
Weekly Report: what happened at CDXS last week (0420-0424)?
Weekly Report · 04/27 10:36
Weekly Report: what happened at CDXS last week (0413-0417)?
Weekly Report · 04/20 10:31
Codexis Board Director Resignation and Governance Rebalancing Announced
TipRanks · 04/14 20:39
More
Webull provides a variety of real-time CDXS stock news. You can receive the latest news about Codexis Inc through multiple platforms. This information may help you make smarter investment decisions.
About CDXS
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.